Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Sold by Wealth Alliance

Wealth Alliance lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 18.5% during the 4th quarter, according to the company in its most recent disclosure with the SEC. The firm owned 457 shares of the biopharmaceutical company’s stock after selling 104 shares during the quarter. Wealth Alliance’s holdings in Regeneron Pharmaceuticals were worth $326,000 at the end of the most recent reporting period.

Other institutional investors have also modified their holdings of the company. Rakuten Securities Inc. grew its position in shares of Regeneron Pharmaceuticals by 380.0% in the third quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock valued at $25,000 after purchasing an additional 19 shares during the period. FSA Wealth Management LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $26,000. Fairfield Financial Advisors LTD acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $37,000. Private Wealth Management Group LLC grew its position in shares of Regeneron Pharmaceuticals by 260.0% in the fourth quarter. Private Wealth Management Group LLC now owns 54 shares of the biopharmaceutical company’s stock valued at $38,000 after purchasing an additional 39 shares during the period. Finally, Truvestments Capital LLC acquired a new stake in shares of Regeneron Pharmaceuticals in the third quarter valued at about $39,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Analyst Ratings Changes

Several brokerages have recently issued reports on REGN. Leerink Partnrs upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research report on Wednesday, February 5th. Canaccord Genuity Group lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a research report on Tuesday, December 17th. Morgan Stanley lowered their price target on shares of Regeneron Pharmaceuticals from $1,235.00 to $1,184.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. StockNews.com lowered shares of Regeneron Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a research report on Monday, November 4th. Finally, Canaccord Genuity Group started coverage on shares of Regeneron Pharmaceuticals in a research report on Tuesday, December 17th. They set a “hold” rating and a $165.00 price target on the stock. One research analyst has rated the stock with a sell rating, six have given a hold rating, seventeen have assigned a buy rating and two have given a strong buy rating to the company’s stock. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and a consensus target price of $973.13.

Regeneron Pharmaceuticals Price Performance

Regeneron Pharmaceuticals stock opened at $700.33 on Friday. The company’s 50 day simple moving average is $699.40 and its 200-day simple moving average is $883.75. The company has a market capitalization of $76.56 billion, a price-to-earnings ratio of 18.29, a price-to-earnings-growth ratio of 2.30 and a beta of 0.08. Regeneron Pharmaceuticals, Inc. has a 1 year low of $642.00 and a 1 year high of $1,211.20. The company has a debt-to-equity ratio of 0.09, a quick ratio of 3.95 and a current ratio of 4.73.

Regeneron Pharmaceuticals (NASDAQ:REGN) last released its quarterly earnings results on Tuesday, February 4th. The biopharmaceutical company reported $12.07 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $11.21 by $0.86. The business had revenue of $3.79 billion for the quarter, compared to the consensus estimate of $3.76 billion. Regeneron Pharmaceuticals had a net margin of 31.07% and a return on equity of 16.32%. The business’s revenue was up 10.3% on a year-over-year basis. During the same period in the previous year, the firm earned $11.86 EPS. As a group, equities research analysts expect that Regeneron Pharmaceuticals, Inc. will post 35.92 earnings per share for the current year.

Regeneron Pharmaceuticals Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, March 20th. Stockholders of record on Thursday, February 20th will be paid a $0.88 dividend. This represents a $3.52 dividend on an annualized basis and a dividend yield of 0.50%. The ex-dividend date of this dividend is Thursday, February 20th.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.